These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 24379381)

  • 41. Influence of growth hormone-releasing hormone (GHRH) on phytohemagglutinin-induced lymphocyte activation: comparison of two synthetic forms. GHRH and PHA-induced lymphocyte activation.
    Valtorta A; Moretta A; Maccario R; Bozzola M; Severi F
    Thymus; 1991 Aug; 18(1):51-9. PubMed ID: 1833862
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
    Rekasi Z; Schally AV; Plonowski A; Czompoly T; Csernus B; Varga JL
    Prostate; 2001 Aug; 48(3):188-99. PubMed ID: 11494334
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bioactivity of growth hormone releasing hormone (1-29) analogues after SC injection in man.
    Aitman TJ; Rafferty B; Coy D; Lynch SS; Clayton RN
    Peptides; 1989; 10(1):1-4. PubMed ID: 2546126
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The expression of growth hormone-releasing hormone (GHRH) and its receptor splice variants in human breast cancer lines; the evaluation of signaling mechanisms in the stimulation of cell proliferation.
    Garcia-Fernandez MO; Schally AV; Varga JL; Groot K; Busto R
    Breast Cancer Res Treat; 2003 Jan; 77(1):15-26. PubMed ID: 12602901
    [TBL] [Abstract][Full Text] [Related]  

  • 45. GH feedback occurs through modulation of hypothalamic somatostatin under cholinergic control: studies with pyridostigmine and GHRH.
    Ross RJ; Tsagarakis S; Grossman A; Nhagafoong L; Touzel RJ; Rees LH; Besser GM
    Clin Endocrinol (Oxf); 1987 Dec; 27(6):727-33. PubMed ID: 2901302
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Agonist of growth hormone-releasing hormone as a potential effector for survival and proliferation of pancreatic islets.
    Ludwig B; Ziegler CG; Schally AV; Richter C; Steffen A; Jabs N; Funk RH; Brendel MD; Block NL; Ehrhart-Bornstein M; Bornstein SR
    Proc Natl Acad Sci U S A; 2010 Jul; 107(28):12623-8. PubMed ID: 20616039
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.
    Villanova T; Gesmundo I; Audrito V; Vitale N; Silvagno F; Musuraca C; Righi L; Libener R; Riganti C; Bironzo P; Deaglio S; Papotti M; Cai R; Sha W; Ghigo E; Schally AV; Granata R
    Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2226-2231. PubMed ID: 30659154
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers.
    Stangelberger A; Schally AV; Zarandi M; Heinrich E; Groot K; Havt A; Kanashiro CA; Varga JL; Halmos G
    Prostate; 2007 Sep; 67(12):1339-53. PubMed ID: 17624923
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.
    Arvat E; Di Vito L; Ramunni J; Gianotti L; Giordano R; Deghenghi R; Camanni F; Ghigo E
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):495-500. PubMed ID: 9404449
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Growth hormone-releasing hormone (GHRH) promotes metastatic phenotypes through EGFR/HER2 transactivation in prostate cancer cells.
    Muñoz-Moreno L; Bajo AM; Prieto JC; Carmena MJ
    Mol Cell Endocrinol; 2017 May; 446():59-69. PubMed ID: 28193499
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cellular mechanisms of growth inhibition of human endometrial cancer cell line by an antagonist of growth hormone-releasing hormone.
    Zhao L; Yano T; Osuga Y; Nakagawa S; Oishi H; Wada-Hiraike O; Tang X; Yano N; Kugu K; Schally AV; Taketani Y
    Int J Oncol; 2008 Mar; 32(3):593-601. PubMed ID: 18292936
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The inhibitory effects of growth hormone-releasing hormone (GHRH)-antagonist on GHRH, L-dopa, and clonidine-induced GH secretion in normal subjects.
    Hanew K; Tanaka A; Utsumi A; Sugawara A; Abe K
    J Clin Endocrinol Metab; 1996 May; 81(5):1952-5. PubMed ID: 8626863
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Responses to analogues of growth hormone-releasing hormone in normal subjects, and in growth-hormone deficient children and young adults.
    Grossman A; Savage MO; Lytras N; Preece MA; Sueiras-Diaz J; Coy DH; Rees LH; Besser GM
    Clin Endocrinol (Oxf); 1984 Sep; 21(3):321-30. PubMed ID: 6236914
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers.
    Klukovits A; Schally AV; Szalontay L; Vidaurre I; Papadia A; Zarandi M; Varga JL; Block NL; Halmos G
    Cancer; 2012 Feb; 118(3):670-80. PubMed ID: 21751186
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.
    Seitz S; Rick FG; Schally AV; Treszl A; Hohla F; Szalontay L; Zarandi M; Ortmann O; Engel JB; Buchholz S
    Oncol Rep; 2013 Jul; 30(1):413-8. PubMed ID: 23624870
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Improvement of cardiac and systemic function in old mice by agonist of growth hormone-releasing hormone.
    Xiang P; Jing W; Lin Y; Liu Q; Shen J; Hu X; Chen J; Cai R; Hare JM; Zhu W; Schally AV; Yu H
    J Cell Physiol; 2021 Dec; 236(12):8197-8207. PubMed ID: 34224586
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The interaction between clonidine and growth hormone releasing hormone in the stimulation of growth hormone secretion in man.
    Suri D; Hindmarsh PC; Brain CE; Pringle PJ; Brook CG
    Clin Endocrinol (Oxf); 1990 Sep; 33(3):399-406. PubMed ID: 2147600
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antagonist of growth hormone-releasing hormone induces apoptosis in LNCaP human prostate cancer cells through a Ca2+-dependent pathway.
    Rekasi Z; Czompoly T; Schally AV; Boldizsar F; Varga JL; Zarandi M; Berki T; Horvath RA; Nemeth P
    Proc Natl Acad Sci U S A; 2005 Mar; 102(9):3435-40. PubMed ID: 15728367
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effect of repeated administration of hexarelin, a growth hormone releasing peptide, and growth hormone releasing hormone on growth hormone responsivity.
    Massoud AF; Hindmarsh PC; Matthews DR; Brook CG
    Clin Endocrinol (Oxf); 1996 May; 44(5):555-62. PubMed ID: 8762732
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Harnessing the cross-talk between tumor cells and tumor-associated macrophages with a nano-drug for modulation of glioblastoma immune microenvironment.
    Li TF; Li K; Wang C; Liu X; Wen Y; Xu YH; Zhang Q; Zhao QY; Shao M; Li YZ; Han M; Komatsu N; Zhao L; Chen X
    J Control Release; 2017 Dec; 268():128-146. PubMed ID: 29051064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.